Tirzepatide (15 mg Vial)

Tirzepatide (15 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Tirzepatide (15 mg Vial)

Synonyms/Alias: Tirzepatide

Purity: Specification by inquiry

Custom Peptide Support

  • Sequence, purity and scale confirmation
  • CoA and technical documentation requests
  • API, research and cosmetic peptide options
  • Distributor and institution quotation support

Tirzepatide (15 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.

Quickstart

Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.

Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).

Easy measuring: At 7.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Notes

Practical considerations for consistency and safety. Use new sterile insulin syringes; dispose in a sharps container [7]. Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation [8]. For multi‑injection doses, use different sites for each injection on the same day. Inject slowly; wait a few seconds before withdrawing the needle. Document weekly dose, date, and injection site to maintain consistency. Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them [1].

Single peptide protocol reference: Available for related research, development or formulation inquiry workflows.

Reconstitution and handling reference: Available for related research, development or formulation inquiry workflows.

Research-use documentation inquiry: Available for related research, development or formulation inquiry workflows.

Weeks 1–4
Weekly Dose (mg): 2.5 mg | Units (per injection) (mL): 33 units (0.33 mL) × 1 injection
Weeks 5–8
Weekly Dose (mg): 5 mg | Units (per injection) (mL): 67 units (0.67 mL) × 1 injection
Weeks 9–12
Weekly Dose (mg): 7.5 mg | Units (per injection) (mL): 100 units (1.0 mL) × 1 injection
Weeks 13–16
Weekly Dose (mg): 10 mg | Units (per injection) (mL): 67 units (0.67 mL) × 2 injections
Long-term Storage Conditions
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Shipping Condition
Shipping conditions by inquiry

Peptide Vials (Tirzepatide, 15 mg each): 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 2 vials

12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 4 vials

16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 7 vials

Insulin Syringes (U‑100, 1 mL): 8 weeks: 8 syringes (1/week)

12 weeks: 12 syringes (1/week)

16 weeks: 20 syringes (1/week wks 1–12, 2/week wks 13–16)

Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution. 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle

12 weeks (4 vials): 8 mL → 1 × 10 mL bottle

16 weeks (7 vials): 14 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each administration day. Per week: 2 swabs (1 injection day)

8 weeks: 16 swabs → recommend 1 × 100‑count box

12 weeks: 24 swabs → recommend 1 × 100‑count box

16 weeks: 32 swabs → recommend 1 × 100‑count box

Product Gallery

Quick Inquiry

Customer Support & Price Inquiry

Send product, purity, quantity, destination and documentation requirements. Quantai will follow up through WhatsApp or email.

Email: kongq687@gmail.com

WhatsAppMia WhatsApp Business QR code

Address: Huangpu District, Guangzhou, China